BR112015025729A2 - métodos para dividir e para produzir um composto, composto, composição farmacêutica, agente profilático ou terapêutico, e, uso de um cristal - Google Patents

métodos para dividir e para produzir um composto, composto, composição farmacêutica, agente profilático ou terapêutico, e, uso de um cristal

Info

Publication number
BR112015025729A2
BR112015025729A2 BR112015025729A BR112015025729A BR112015025729A2 BR 112015025729 A2 BR112015025729 A2 BR 112015025729A2 BR 112015025729 A BR112015025729 A BR 112015025729A BR 112015025729 A BR112015025729 A BR 112015025729A BR 112015025729 A2 BR112015025729 A2 BR 112015025729A2
Authority
BR
Brazil
Prior art keywords
compound
prophylactic
dividing
producing
pharmaceutical composition
Prior art date
Application number
BR112015025729A
Other languages
English (en)
Other versions
BR112015025729B1 (pt
Inventor
Hasegawa Gen
Nagasawa Hiroshi
Watanabe Masashi
Kawahara Michiaki
Sato Noritada
Okachi Takahiro
Takita Takashi
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of BR112015025729A2 publication Critical patent/BR112015025729A2/pt
Publication of BR112015025729B1 publication Critical patent/BR112015025729B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1 / 1 resumo “mã‰todos para dividir e para produzir um composto, composto, composiã‡ãƒo farmacãšutica, agente profilãtico ou terapãšutico, e, uso de um cristal” provãª-se um intermediã¡rio na fabricaã§ã£o de um atropisomero de um dipirrometeno que tem um excelente antagonismo receptor mineralocorticã³ide, um mã©todo para fabricar o mesmo e cristais do mesmo. um mã©todo para fabricar um atropisomero de um dipirrometeno que inclui a 1 etapa de dividir o atropisomero da fã³rmula geral (i) [na fã³rmula, r ã© um 2 grupo metila ou um grupo trifluorometila, r ã© um ã¡tomo de hidrogãªnio ou um grupo alcã³xi c1-c3 e n ã© um inteiro selecionado de 1 a 3], distinguido pela utilizaã§ã£o de uma amina ativa opticamente que tem um esqueleto cinchona e cristais de (s)-1-(2- hidroxietil)-4-metil-n-[4- (metilsulfonil) fenil] -5- [2- (trifluorometil) fenil] -1h-pirrole-3-carboxamida.
BR112015025729-1A 2013-04-10 2014-04-07 Métodos para resolver e para produzir um composto BR112015025729B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013081879 2013-04-10
JP2013-081879 2013-04-10
PCT/JP2014/060055 WO2014168103A1 (ja) 2013-04-10 2014-04-07 ピロール誘導体の結晶及びその製造方法

Publications (2)

Publication Number Publication Date
BR112015025729A2 true BR112015025729A2 (pt) 2017-07-18
BR112015025729B1 BR112015025729B1 (pt) 2023-04-25

Family

ID=51689511

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015025729-1A BR112015025729B1 (pt) 2013-04-10 2014-04-07 Métodos para resolver e para produzir um composto

Country Status (13)

Country Link
US (3) US9499483B2 (pt)
EP (2) EP3190102B1 (pt)
JP (2) JP6240164B2 (pt)
KR (2) KR20210018557A (pt)
CN (2) CN106916092B (pt)
BR (1) BR112015025729B1 (pt)
CA (2) CA2958625C (pt)
ES (2) ES2700962T3 (pt)
HK (1) HK1221214A1 (pt)
HU (2) HUE041725T2 (pt)
IL (2) IL241892B (pt)
TW (1) TWI624447B (pt)
WO (1) WO2014168103A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE037007T2 (hu) 2013-08-27 2018-08-28 Daiichi Sankyo Co Ltd Eljárás pirrol származék elõállítására és annak intermediere
JP6934859B2 (ja) * 2016-03-24 2021-09-15 第一三共株式会社 腎疾患の治療のための医薬
TW202135802A (zh) * 2019-12-25 2021-10-01 日商第一三共股份有限公司 包含吡咯羧醯胺之口腔崩散錠
JPWO2021167095A1 (pt) * 2020-02-21 2021-08-26
WO2022206666A1 (zh) * 2021-03-30 2022-10-06 广东东阳光药业有限公司 吡咯酰胺化合物的晶型及其制备方法和用途
CN115246785B (zh) * 2021-04-26 2024-03-26 年衍药业(珠海)有限公司 吡咯酰胺化合物的制备方法
CN113651745B (zh) * 2021-09-09 2023-06-02 上海医药工业研究院 布瓦西坦中间体及其制备方法和纯化方法
CN115784961A (zh) * 2021-09-10 2023-03-14 上海鼎雅药物化学科技有限公司 埃沙西林酮及其中间体的合成方法
WO2023134677A1 (zh) * 2022-01-14 2023-07-20 广东东阳光药业有限公司 制备吡咯化合物的方法及其中间体
CN114456098A (zh) * 2022-01-19 2022-05-10 大连理工大学 糖尿病肾病药物艾莎利酮的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11279158A (ja) * 1998-02-09 1999-10-12 Pfizer Prod Inc キナゾリン―４―オン誘導体の製造方法
NZ519984A (en) * 2000-01-07 2004-03-26 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
US6939968B2 (en) * 2002-12-23 2005-09-06 Bristol-Myers Squibb Company Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives
JP4703649B2 (ja) * 2004-07-30 2011-06-15 エグゼリクシス， インコーポレイテッド 薬学的因子としてのピロール誘導体
CN101006052B (zh) * 2004-07-30 2013-11-06 埃克塞利希斯股份有限公司 作为药用制剂的吡咯衍生物
KR100770434B1 (ko) 2006-11-07 2007-10-26 여석준 다층 다단 다공성 플레이트에 의한 입자 분리·포집시스템
CN101679243B (zh) 2007-04-09 2012-09-26 第一三共株式会社 吡咯衍生物的阻转异构体
JP2010111657A (ja) * 2008-10-07 2010-05-20 Daiichi Sankyo Co Ltd ピロール誘導体のアトロプ異性体を含有する医薬
WO2010098286A1 (ja) * 2009-02-25 2010-09-02 第一三共株式会社 ミネラルコルチコイド受容体拮抗薬を含有する医薬

Also Published As

Publication number Publication date
CA2908879C (en) 2018-05-15
EP3190102A1 (en) 2017-07-12
CA2908879A1 (en) 2014-10-16
KR20150139854A (ko) 2015-12-14
CN105164105A (zh) 2015-12-16
JP6240164B2 (ja) 2017-11-29
WO2014168103A1 (ja) 2014-10-16
CN106916092A (zh) 2017-07-04
US9676713B2 (en) 2017-06-13
US9776961B2 (en) 2017-10-03
EP2985277A4 (en) 2016-11-23
US20170057915A1 (en) 2017-03-02
CN106916092B (zh) 2019-07-19
CA2958625C (en) 2019-05-28
JP2017141274A (ja) 2017-08-17
JPWO2014168103A1 (ja) 2017-02-16
CA2958625A1 (en) 2014-10-16
TW201518253A (zh) 2015-05-16
IL260782B (en) 2019-02-28
EP2985277A1 (en) 2016-02-17
HUE038950T2 (hu) 2018-12-28
EP2985277B1 (en) 2018-01-17
KR20210018557A (ko) 2021-02-17
ES2700962T3 (es) 2019-02-20
US9499483B2 (en) 2016-11-22
IL241892B (en) 2020-02-27
US20170233341A1 (en) 2017-08-17
EP3190102B1 (en) 2018-09-12
BR112015025729B1 (pt) 2023-04-25
ES2661125T3 (es) 2018-03-27
CN105164105B (zh) 2018-01-30
KR102234597B1 (ko) 2021-03-31
JP6511083B2 (ja) 2019-05-15
HUE041725T2 (hu) 2019-05-28
US20160096803A1 (en) 2016-04-07
HK1221214A1 (zh) 2017-05-26
TWI624447B (zh) 2018-05-21

Similar Documents

Publication Publication Date Title
BR112015025729A2 (pt) métodos para dividir e para produzir um composto, composto, composição farmacêutica, agente profilático ou terapêutico, e, uso de um cristal
ECSP16005566A (es) Sulfonamidas como moduladores de canales de sodio
CL2014003181A1 (es) Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas.
SMT201300098B (it) Forme solide di N-(4-(7-azabiciclo[2.2.1]eptan-7-il)-2-(trifluorometil)fenil-4-osso-5-trifluorometil)-1,4-diidrochinolina-3-carbossammide
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
EA201691302A1 (ru) Новые гетероциклические соединения
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
EA200970156A1 (ru) Пиридизиноновые производные
JOP20200159A1 (ar) مثبطات إندونيوكلياز معتمدة على cap
BR112016006651A8 (pt) derivados de quinolizina substituídos, composição farmacêutica que os compreede e uso dos mesmos.
WO2014145214A3 (en) Inhibitors of prmt5 and methods of their use
EA201391313A1 (ru) C4-монометилтритерпеноидные производные и способы их применения
AR062074A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa
BR112015014222A2 (pt) composto, composição farmacêutica, uso de um composto, método para o tratamento de anemia e composição farmacêutica
CL2010001348A1 (es) Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad.
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
UA109525C2 (xx) Алкіламідна сполука і її застосування
ECSP11011048A (es) Inhibidores de cinasa akt y p70 s6
EA201390163A1 (ru) Гетеробициклические производные в качетстве ингибиторов hcv
CR20110484A (es) Nuevos derivados de benzotiazepinas su procedimiento de preparacion y composiciones farmaceuticas que los contienen
CU23761B7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR109991A1 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas
UY37016A (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
AR091687A1 (es) Formas solidas de inhibidores de fosfodiesterasa tipo 5

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/04/2014, OBSERVADAS AS CONDICOES LEGAIS